| Identification | Back Directory | [Name]
(R)-3-(4-(2-(4-((S)-2-acetoxy-3-chloropropoxy)phenyl)propan-2-yl)phenoxy)propane-1,2-diyl diacetate | [CAS]
1637573-04-6 | [Synonyms]
Ralaniten triacetate
Ralaniten triacetate(EPI-506)
(R)-3-(4-(2-(4-((S)-2-acetoxy-3-chloropropoxy)phenyl)propan-2-yl)phenoxy)propane-1,2-diyl diacetate
(S)-3-(4-(2-(4-((S)-2-acetoxy-3-chloropropoxy)phenyl)propan-2-yl)phenoxy)propane-1,2-diyl diacetate
1,2-Propanediol, 3-[4-[1-[4-[(2S)-2-(acetyloxy)-3-chloropropoxy]phenyl]-1-methylethyl]phenoxy]-, 1,2-diacetate, (2S)- | [Molecular Formula]
C27H33ClO8 | [MDL Number]
MFCD31631681 | [MOL File]
1637573-04-6.mol | [Molecular Weight]
521 |
| Chemical Properties | Back Directory | [Boiling point ]
619.0±55.0 °C(Predicted) | [density ]
1.188±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (191.94 mM; Need ultrasonic) | [form ]
Liquid | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
Ralaniten triacetate (EPI-506), the pro-agent of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7[1][2]. | [storage]
Store at -20°C | [References]
[1] Obst JK, et al. Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. ACS Pharmacol Transl Sci. 2019;2(6):453-467. Published 2019 Sep 26. DOI:10.1021/acsptsci.9b00065
[2] Chi, Kim Nguyen et al. Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone. Journal of Clinical Oncology 35 (2017): 5032-5032. |
|
|